DWC202313, DWC202314

DRUG3 trials

Sponsors

Daewoong Pharmaceutical Co. LTD.

Conditions

Essential HypertensionHealthy Volunteers

Phase 1

Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions

RecruitingNCT07260851

Daewoong Pharmaceutical Co. LTD.Healthy Volunteers

Start: 2025-11-05End: 2026-05-30Target: 40Updated: 2025-12-17

Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.

RecruitingNCT07267221

Daewoong Pharmaceutical Co. LTD.Healthy Volunteers

Start: 2025-12-01End: 2026-05-30Target: 36Updated: 2025-12-05

Phase 3

A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension

CompletedNCT06671392

Daewoong Pharmaceutical Co. LTD.Essential Hypertension

Start: 2025-02-24End: 2026-02-05Updated: 2026-03-19